Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Hib Vaccine Wind-Up, Development Flop Trigger GSK, Daiichi Sankyo to Shutter JV
November 15, 2018
- Meiji Seika Pharma to Venture into Eye-Care Field in Indonesia in Collaboration with Santen
November 15, 2018
- Nichi-Iko Places Top Priority on Product Launches in the US in Biosimilar Business: President
November 14, 2018
- GSK, Daiichi Sankyo Dissolve Vaccine JV
November 14, 2018
- Sumitomo Dainippon Establishes JV with Sumitomo Bakelite through Transfer of Diagnostics Biz
November 13, 2018
- Santen Aims at 1st-Line Use of Eybelis for Glaucoma Treatment: President
November 13, 2018
- Big Takeda Could Debut as Early as January 8, De-facto Vote on Shire Deal Set for Dec. 5
November 13, 2018
- Takeda: De-facto Vote on Shire Deal Set for Dec. 5
November 12, 2018
- Japan Is Top Strategic Market for Biogen: CEO
November 12, 2018
- Ethical Drug Sales Down 8.1% in September: Crecon
November 12, 2018
- Avastin Tops Japan Sales Ranking for 3 Months on End: Encise Snapshot
November 12, 2018
- Nippon Kayaku’s Herceptin Biosimilar to Foray into Breast Cancer Arena, following Daiichi Sankyo, Pfizer
November 12, 2018
- Eisai Launches Full-Scale Operations at New China Plant, Doubling Production Capacity
November 12, 2018
- EA Pharma Pairs Up with 6 Institutions on Joint Research on Novel Antibody for Crohn’s Disease
November 9, 2018
- Maviret Retains Top Spot in Japan Drug Ranking in July-September: IQVIA
November 8, 2018
- Nippon Shinyaku Preparing for Clinical Studies of 5 Oligonucleotide Drugs to Cover 50% of DMD Patients: Pres.
November 8, 2018
- Takeda Launches Entyvio in Japan for Ulcerative Colitis
November 8, 2018
- Aspen Taking Over Anexate from Astellas
November 7, 2018
- Kyowa Kirin License Novel Blood Cancer Treatment from US Company
November 7, 2018
- EMA Accepts Quizartinib Application, with Accelerated Assessment Status: Daiichi Sankyo
November 7, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…